CRISPR–Cas gene editors are now both moving into the clinic and being embraced as a means to find and validate drug targets. But for Jennifer Doudna, who helped pioneer this promise with her work at UC Berkeley, the full potential of these tools will only be unleashed when they can be used at scale. To this end, Doudna and colleagues partnered last year with GlaxoSmithKline to launch the Laboratory for Genomic Research (LGR), a US$67 million effort aimed at industrializing the CRISPR–Cas workflow for the detailed exploration of human genetics. One year on, she spoke with Asher Mullard about her hopes for CRISPR–Cas editors as drug discovery tools, the types of projects the LGR is working on and the challenges they face.

中文翻译：

---

珍妮佛·杜娜（Jennifer Doudna）。

CRISPR–Cas基因编辑器现在正进入临床领域，并被视为寻找和验证药物靶标的一种手段。但是对于詹妮弗·杜德纳（Jennifer Doudna）（她在UC Berkeley的工作中帮助实现了这一诺言）来说，只有在大规模使用这些工具后，这些工具的全部潜力才能发挥出来。为此，Doudna及其同事去年与GlaxoSmithKline合作启动了基因组研究实验室（LGR），该项目耗资6700万美元，旨在实现CRISPR-Cas工作流程的工业化，以详细探索人类遗传学。一年后，她与Asher Mullard谈了她对CRISPR–Cas编辑器作为药物发现工具的希望，LGR正在开展的项目类型以及他们面临的挑战。